Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

PURPOSE: Chemotherapy resistance remains a major problem in many solid tumors, including breast, ovarian, and pancreatic cancer. Glucocorticoids are one potential driver of chemotherapy resistance as they can mediate tumor progression via induction of cell-survival pathways. We investigated whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Munster, Pamela N., Greenstein, Andrew E., Fleming, Gini F., Borazanci, Erkut, Sharma, Manish R., Custodio, Joseph M., Tudor, Iulia Cristina, Pashova, Hristina I., Shepherd, Stacie Peacock, Grauer, Andreas, Sachdev, Jasgit C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662918/
https://www.ncbi.nlm.nih.gov/pubmed/35583817
http://dx.doi.org/10.1158/1078-0432.CCR-21-4363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662918/
https://www.ncbi.nlm.nih.gov/pubmed/35583817
http://dx.doi.org/10.1158/1078-0432.CCR-21-4363

Ejemplares similares